Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
|Articles|May 2, 2017
AbbVie Contract Manufacturing
Advertisement
AbbVie’s Contract Manufacturing business has been serving our partners for over 35 years. Our contract/toll development and manufacturing capabilities span Fermentation, Drug Product, Potent, Hot Melt Extrusion, Prefilled Syringes, Biologics, and Bulk Active Pharmaceutical Ingredients (APIs) across 10 production facilities in North America and Europe.
1401 Sheridan Rd, North Chicago, IL 60064
abbviecontractmfg@abbvie.com
tel. 1.847.938.8524
CPhI North America Booth #2218
Advertisement
Related to this article
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Advertisement
Advertisement